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ABSTRACT
The risk of cardiovascular disease is higher in chronic kidney disease patients compared to the general 
population and its impact is higher in developing countries compared to the developed countries. With 
this background in mind, we aimed to evaluate the prevalence of different cardiovascular risk factors 
in patients on maintenance hemodialysis in a tertiary care center. Chronic kidney disease patients 
aged 18 years and above who were under maintenance hemodialysis in the hemodialysis unit of Nepal 
Medical College were included in the study. Pre-dialysis venous blood samples from the participants 
were collected and analyzed for serum calcium, phosphorus, total protein, albumin and hemoglobin. 
Calcium phosphate product was calculated. Out of 100 study participants, 52% were male and 48% 
were female. Age-wise distribution showed 38% of the participants were below 40 years. The mean 
age of the participants was 45.86 ± 14.4 years. Ninety-three percent had hypertension and 29% had 
diabetes mellitus. Hypocalcemia was present in 80%, hyperphosphatemia was seen among 81% and 
high calcium phosphate product was present in 33% of the participants. Low hemoglobin (< 10gm/dL) 
was found in 86%. The cardiovascular risk trend in the Nepalese chronic kidney disease population 
is fairly different compared to the western population. Participants were younger. Prevalence of 
hypertension and diabetes was high. The high prevalence of anemia might be due to unaffordability 
of the participants for regular erythropoietin therapy. Inadequately managed hyperphosphatemia 
despite the widespread use of phosphorus binders, is still a major clinical challenge in patients on 
hemodialysis.
1Department of Biochemistry, Nepal Medical College & Teaching Hospital, Kathmandu, Nepal, 2Priority Research Centre for 
Stroke and Brain Injury, School of Biomedical Sciences and Pharmacy, University of Newcastle, New South Wales, Australia, 
3Department of Biochemistry, Universal College of Medical Sciences, Bhairahawa, Nepal, 4Hemodialysis unit, Department of 
Medicine, Nepal Medical College and Teaching Hospital, Kathmandu, Nepal, 5Faculty of Sciences, Charles Sturt University, 
NSW Australia
Corresponding author
Dr. Asmita Pokhrel
Lecturer, Department of Biochemistry, 
Nepal Medical College Teaching Hospital,
Kathmandu, Nepal
Email: dr.asmita321@gmail.com
ORCID ID: 0000-0002-5739-6056
https://doi.org10.3126/nmcj.v21i4.27629
Keywords
Cardiovascular risk, chronic 
kidney disease, hemodialysis, 
anemia, calcium phosphate 
product
Original Article Nepal Med Coll J 2019; 21(4): 313-8
Prevalence of cardiovascular risk factors among chronic kidney 
disease patients undergoing hemodialysis in a tertiary care center, 
Kathmandu, Nepal
Pokhrel A,1 Gyawali P,2 Pokhrel BR,3 Khanal MP,1 Manandhar DN,4 Bwititi P,5 Nwose EU5
Nepal Medical College Journal
314 NMCJ
INTRODUCTION
Chronic kidney disease (CKD) is a global epidemic 
with more than a million people on dialysis or with 
a functioning graft worldwide.1 Global prevalence 
of CKD in the general population is 13.4%,2 while 
it is reported as 10.6% in Nepal.3
The rationale of dialysis is removing toxic 
nitrogenous waste products and excess fluid from 
the body and correcting acid-base disorders. 
Apart from urea, creatinine, albumin, total 
protein, sodium, potassium; abnormal levels of 
hemoglobin (Hb), calcium (Ca) and phosphorus 
(P) in blood have been identified as pre dictors 
of survival in patients undergoing main tenance 
hemodialysis.4 Moreover, age, hypertension, 
diabetes and physical inactivity are considered as 
the major contributors of cardiovascular disease 
(CVD) in hemodialysis patients.5
Anemia, a common complication seen in 
hemodialysis patients  is associated with increased 
risk for cardiovascular morbidity and mortality. 
Possible explanations include reduction in tissue 
oxygenation, increase in cardiac output, reduction 
in the capacity for exercise and left ven tricular 
hypertrophy. Moreover, anemia reduces patients’ 
quality of life and con tributes to shortened life 
span.6,7
Hyperphosphatemia has long been suggested 
as an independent risk factor for all-cause and 
cardiovascular mortality in CKD patients and 
lowering serum P levels were found to improve 
clinical outcomes.8 Similarly, elevated calcium 
phosphate product (Ca x P) has been linked with 
CVD complications in later stages of CKD in many 
studies. Possible mechanisms include vascular 
calcification, endothelial dysfunction, myocardial 
hypertrophy and cardiac malfunctions.9 However, 
in many cross-sectional and longitudinal studies, 
vascular calcification did not correlate with Ca x 
P or serum Ca or P.10,11
CKD is associated with huge economic burden and 
the impact of this burden is disproportionately 
high in low-income countries like Nepal where the 
most important risk factors for CKD, hypertension 
and diabetes mellitus, are rising.12 Diabetic 
nephropathy is the commonest cause of end-
stage renal disease (ESRD) in the USA followed by 
hypertensive nephropathy.13 A systemic review 
has shown the pooled prevalence of CKD is 10.1% 
in the general population, 24.7% in hypertensive, 
and 16.6% among diabetes mellitus patients in 
Africa.14
Due to poverty and poor education, the burden 
posed by complications of CKD is more in 
developing countries.15 Hence, the clinical 
scenario of dialysis patients in economically 
constrained countries like Nepal may be 
different from the developed  countries with 
strong economies sufficient enough to meet the 
challenges posed by CKD. With this background 
in mind, we aimed to evaluate the prevalence 
of different cardiovascular risk factors in CKD 
patients on hemodialysis in a tertiary care center.
MATERIALS AND METHODS
Ethical approval was obtained from the 
Institutional Review Committee of Nepal Medical 
College Teaching Hospital (NMCTH), Kathmandu, 
Nepal. A hospital-based descriptive cross-
sectional study was conducted from September  to 
December 2017 among 100 patients. CKD patients 
aged 18 years and above, who were under 
maintenance hemodialysis in the hemodialysis 
unit of NMCTH, were included in the study. 
Patients were explained about the study and 
verbal consent was taken. Convenient sampling 
technique was used. Pre-dialysis venous blood 
samples were collected from the participants 
following standard aseptic protocol and serum 
were analyzed for Ca, P, total protein and 
albumin by dry chemistry using Vitros 250. Ca 
x P was calculated. Hb was estimated in coulter 
counter, Sysmex XS-500i. Serum Ca level <9mg/
dL was considered low and between 9-11mg/
dL was considered normal. Similarly, serum P 
>4.5mg/dL was considered high. Ca x P >55 mg2/
dL2 was considered high. Hb level <10gm/dL was 
considered low, serum total protein <6gm/dL and 
albumin <3.5gm/dL were considered low.16 Other 
demographic and medical details were noted from 
the patients’ medical records on the day of sample 
collection. Data were analyzed using Epi Info 7. 
Descriptive statistical tools were employed. The 
mean and standard deviation of numerical data 
were calculated, both overall and gender-wise. 
Prevalence of CVD risk factors was expressed as 
percentages.
Fig. 1: Age wise distribution of the study 
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RESULTS
Among a total of 100 study participants, 52% were 
male and 48% were female. Age-wise distribution 
showed 38% of participants were below 40 years. 
Details are presented in Figure 1.The mean age 
of the participants was 45.86 ± 14.4 years. The 
baseline characteristics of the study participants 
are presented in Table 1.
In terms of participants’ clinical history, 40% 
were past smokers, 49% were past alcohol users 
while 29% had both habits in the past. Ninety-
three percent had hypertension, 29% had diabetes 
mellitus (Table 2).
Hypocalcemia was present in 80%, 
hyperphosphatemia was seen among 81% and 
high Ca x P was seen in 33% of the participants. 
Hb, total protein and albumin were low in 86%, 
56% and 38% respectively (Table 3).
DISCUSSION
The present study on cardiovascular risk profiling 
in hemodialysis patients has highlighted some 
important cardiovascular issues in the Nepalese 
CKD population. The findings hint towards 
different demographics and cardiovascular risk 
trend in our population when compared to the 
developed countries.  
To start with, 38.0% of our participants were under 
the age of 60. The mean age of the hemodialysis 
patients in the present study is 45.86 ± 14.4 years. 
Other studies from Nepal have also revealed mean 
age of 42.33 ± 15 years,17 and 50.92 ± 17.98 years,18 
in contrast to 65 years or above, as reported in 
several larger international studies.19,20 A study 
in India also revealed the median age of 43 years 
among the ESRD patients.21 The consistent lower 
age trend for hemodialysis in our country might 
be attributed to the lack of health promotion and 
no good access to better health care in terms 
of early screening, preventing, detecting and 
managing CKD risk factors such as hypertension 
or diabetes.
Table 1: Demographic and clinical data of the study participants
Mean ± SD Overall (n = 100) Male (n = 52) Female (n = 48)
Age (years) 45.8 ± 14.4 45.6 ± 15.5 46.1 ± 13.3
Ca (mg/dL) 7.9 ± 1.1 7.9 ± 1.1 8.0 ± 1.1
P (mg/dL) 6.1 ± 1.8 6.2 ± 1.6 5.9 ± 1.9
Ca X P (mg2/dl2) 48.7 ±  15.3 49.6 ± 14.8 47.7 ± 15.8
Total Protein (gm/dL) 5.9 ± 0.6 5.9 ± 0.6 5.8 ± 0.7
Albumin (gm/dL) 3.6 ± 0.4 3.6 ± 0.4 3.6 ± 0.4
Hb (gm/dL) 8.8 ± 1.8 9.0 ± 1.9 8.6 ± 1.8
Hematocrit (%) 26.8 ± 5.5 27.1 ± 5.7 26.4 ± 5.3   
Duration of dialysis (months) 24.1 ± 17.8 24.4 ± 19.4 23.8 ± 16.0
Table 2: Comorbidity and habits of the study 
participants
Prevalence of cardiovascular risk factors %
Hypertension 93
Diabetes 29
Past smoking 40
Past alcohol users 49
Table 3:  Biochemical profile of the study 
participants
All    
(n=100) 
%
Male    
(n=52) 
%
Female 
(n=48) 
%
Hypocalcemia 80 43 37
Hyperphosphatemia 81 45 36
High Ca x P 33 19 14
Low Hb 86 43 43
Low Total Protein 56 28 28
Low albumin 38 17 21
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The prevalence of hypertension among adults 
20 years and above was 34.0%,22 and that of 
diabetes among general population of 15 years 
and above was 8.4% in Nepal.23 In the present 
study, 93.0% of the patients under maintenance 
hemodialysis had hypertension and 29.0% had 
diabetes. Other similar studies from Nepal have 
also reported a high prevalence of hypertension 
and diabetes in CKD patients,17,18,24,25 compared 
to international studies.26-28 Other than limited 
access to contemporary health care practices, 
factors such as urbanization, poor dietary habits 
and sedentary lifestyle, maybe responsible for 
the increasing prevalence of hypertension and 
diabetes in the context of Nepal which in turn 
leads to CKD progressing to ESRD.29
Anemia which is a common complication in 
dialysis patients is mainly due to reduction 
in erythropoietin (EPO) concentration. In the 
present study, 86.0% participants had low Hb 
(<10gm/dL). The average Hb was 8.8 ± 1.8 gm/dL 
while the recommended target Hb was 11-13 gm/
dL.30 Though common, such a high prevalence 
is unexpected especially when they are under 
maintenance hemodialysis. However, most of the 
patients in our setting were unable to afford the 
cost of regular EPO therapy and they preferred 
blood transfusion for anemia correction. Along 
with this, inadequate and improper nutrients 
may also contribute to low Hb. Similar results 
were obtained in the study conducted at NMCTH 
back in 2008.17 Nepal Government has offered 
free dialysis twice a week  to the needy CKD 
patients from 2016 onwards. However, this 
service does not cover medication cost.31 Hence, 
newer health policies  which offer coverage for 
basic medications as well as sufficient dialysis 
packages for the patients will be much helpful in 
improvement and  management of this critically 
ill group of patients. 
Most of the participants in our study were 
physically inactive. Physical activity has been 
recommended by Kidney Disease Outcomes 
Quality Initiative clinical practice guidelines as 
part of the management of CVD state in all dialysis 
patients.32 Various preliminary studies have also 
attested the positive outcomes of physical activity 
on CVD mortality in hemodialysis patients.33 
This is intricately linked to the anemic state of 
most of the patients, as physical inactivity in 
the anemic state may precipitate dyspnea. Such 
inter-relationships of CVD risk factors should 
be properly analyzed and addressed to improve 
hemodialysis patient status and overall quality 
of life. Probably, this might be an area of scope 
for us to work upon to lower the CVD risk burden 
in this medically compromised group of  dialysis 
patients in our context. 
In the present study, 80.0% had hypocalcemia and 
81.0% had hyperphosphatemia inspite of therapy 
with calcium-containing phosphate binders. 
This finding gave us enough ground to say that 
hypocalcemia and/or hyperphosphatemia could 
have been probable in all of the patients if they 
were not under medication. The high prevalence 
of hyperphosphatemia in the present study 
indicates an area that needs serious attention. 
However, these findings need validation from 
large scale studies. 
Though considered as an independent predictor 
of cardiovascular risk, a high Ca x P  was found 
among 33.0% of the participants in the present 
study. This can be explained by the almost 
equal prevalence of hypocalcemia (80.0%) and 
hyperphosphatemia (81.0%) among the patients 
which resulted into normal Ca x P. Moreover, 
the clinical utility of Ca x P for cardiovascular 
risk assessment is still questionable as it lacks 
a scientific basis. Many studies claim that Ca × 
P is a grossly oversimplified and scientifically 
flawed approach to the problem of ectopic 
calcification.34,35
The cardiovascular risk trend in the Nepalese 
CKD population is fairly different when 
compared to western population. Patients are 
younger and have high prevalence of diabetes, 
hypertension and anemia. The high prevalence 
of anemia might be due to insufficient use of 
EPO, because of poverty. Inadequately managed 
hyperphosphatemia despite the widespread use 
of phosphorus binders, is still a major clinical 
challenge in patients on dialysis.
The observations from this study showed 
that Ca x P may not be applicable for 
screening cardiovascular risk in hemodialysis 
patients, especially given the hypocalcemia/
hyperphosphatemia status that requires calcium 
supplement and phosphate binders. 
Health policies that offer sufficient dialysis 
and basic regular medications for the dialysis 
patients will help in effective management of 
complications of CKD. Incorporation of exercise 
into the dialysis session may help to lower the 
CVD risk factors to some extent. Longitudinal and 
larger-scale studies are recommended. 
LIMITATIONS: The cross-sectional design of the 
study, small sample size and lack of comparison 
group were the limitations of this study.
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